Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Wolfe

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Neurology. Clinical Practice|December 20, 2018
Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy studyTodd D Levine, Jonathan S Katz, Richard Barohn, et al.
Antiviral Therapy|June 26, 2008
HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, VietnamHien Tran Nguyen, Nguyen Bui Duc, Ritu Shrivastava, et al.
The Lancet. Neurology|January 25, 2025
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAli A Habib, Chongbo Zhao, Inmaculada Aban, et al.
Muscle & Nerve|November 3, 2009
Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experienceMamatha Pasnoor, Gil I Wolfe, Sharon Nations, et al.
Journal of the Peripheral Nervous System : JPNS|December 3, 2003
Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathyAlan R Berger, Walter G Bradley, Thomas H Brannagan, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Annals of Neurology|March 13, 2008
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophyKathryn R Wagner, James L Fleckenstein, Anthony A Amato, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Neurology. Clinical Practice|December 20, 2018
Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy studyTodd D Levine, Jonathan S Katz, Richard Barohn, et al.
Antiviral Therapy|June 26, 2008
HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, VietnamHien Tran Nguyen, Nguyen Bui Duc, Ritu Shrivastava, et al.
The Lancet. Neurology|January 25, 2025
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAli A Habib, Chongbo Zhao, Inmaculada Aban, et al.
Muscle & Nerve|November 3, 2009
Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experienceMamatha Pasnoor, Gil I Wolfe, Sharon Nations, et al.
Journal of the Peripheral Nervous System : JPNS|December 3, 2003
Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathyAlan R Berger, Walter G Bradley, Thomas H Brannagan, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Annals of Neurology|March 13, 2008
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophyKathryn R Wagner, James L Fleckenstein, Anthony A Amato, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Pageof 20